Much evidence has accumulated implicating the p53 gene as of importance in breast carcinogenesis. However, much still remains to be uncovered on the specific downstream pathways influenced by this important activator/repressor of transcription. This study investigated the effects of a p53 null genotype on the transcriptome of 'normal' mouse mammary epithelium using a unique in vivo model of preneoplastic transformation. We used SAGE for the comparative analysis of p53 wild type (wt) and null mammary epithelium unexposed and exposed to hormonal stimulation. Analysis of the hormone exposed samples provided a comprehensive view of the dramatic changes in gene expression as consequence of the functional differentiation of the mammary epithelium in an in vivo system. We detected the dysregulation in p53 null epithelium of 51% of the transcriptome. Changes in expression affected not only known p53 target genes, but also several unexpected genes such as Expi (Wdnm1), Cyp1b1, Gelsolin, Ramp2 and class I MHC genes. The dysregulation of specific genes and their potential use as preneoplastic markers was further validated using an independent model of premalignant mammary outgrowth lines. This is the first study to examine the transcriptome of very early stages of preneoplastic progression in an in vivo model that mimics human breast cancer.
Introduction
The frequent involvement of mutations affecting the p53 tumor suppressor gene in breast cancer has been well documented (Elledge and Allred, 1994) . This gene was found to be mutated or aberrantly expressed in 30 -40% of human breast cancers (Elledge and Allred, 1994) . Most of the mutations found in p53 result in loss of function although activating mutations were also observed. Usually p53 abnormalities associate with poorer clinical outcome. This, likely, is the consequence of the known critical roles of p53 in regulating the cell cycle, apoptosis, DNA repair and maintaining genome stability (Levine, 1997) . The loss of wild type p53 function is clearly an important event in breast tumorigenesis as documented both in human and murine systems (Donehower et al., 1995; Elledge and Allred, 1994) . However, the exact mechanisms by which such lack of normal gene function leads to cancer formation and progression are only beginning to be understood.
The generation and characterization of mouse models with p53 deletions and mutations has played an important role in our understanding of some of these mechanisms. Of particular interest have been p53 knock out mice and the mammary gland targeted transgenic mice with ectopically expressed mutant versions of p53 (Donehower et al., 1995; Li et al., 1998) . These models have demonstrated that p53 loss or mutation contributes to enhanced tumorigenic potential by abrogation of apoptosis, increased cell proliferation and increased genomic instability (Donehower et al., 1995; Li et al., 1998) . However the specific downstream targets and mechanisms responsible for exerting such critical phenotypic changes have not been clearly delineated.
Since p53 is a transcription factor that can act either as activator or repressor of gene expression it becomes of relevance to identify novel genes that are affected in their expression, either directly or indirectly, by the lack of p53 function. Most previous p53 related global gene expression studies have been performed using in vitro cell culture models (Polyak et al., 1997; Zhao et al., 2000) . Very little is known about the effects that the absence of p53 function exerts on general gene expression at the in vivo level. It is then important to analyse the effects of a p53 null genotype on gene expression profiles using relevant target tissues in their in vivo context.
In order to study the early effects of lack of p53 function on global gene expression in the mammary epithelium, we utilized a recently developed model of mammary epithelial preneoplastic progression (Jerry et al., 2000) . This model is based on the intra-mammary fat pad transplantation of mammary epithelial cells from p53 null and wt mice into syngeneic hosts combined with the use of pituitary isografts that provide the necessary hormonal milieu for maximal growth stimulation and tumorigenesis (Jerry et al., 2000) . These investigators demonstrated that the lack of p53 function renders the mammary epithelial cells extremely susceptible for adenocarcinoma formation (62% of cases at 14 months for p53 null cells compared with 0% for the wt cells). Susceptibility reaches 100% of cases with a decreased tumor latency period when the host mice are exposed to hormonal treatment (i.e. pituitary isografts) while still remaining at 0% in the p53 wt cells (Jerry et al., 2000) . In the present study, we focused our analysis on untreated mammary gland and on hormonally stimulated mammary epithelium at time periods long before evidence of premalignant progression can be histopathologically detectable. To perform the comparative gene expression profiling we used SAGE, a powerful global gene expression methodology that allows for the quantitative evaluation of all cellular mRNA species (Velculescu et al., 1995) . These studies allowed us not only to identify differentially expressed genes in the p53 null samples but also to obtain a global view of the dramatic physiologic effects in the normal mammary epithelium resulting from the hormonal exposure that emulates a late pregnant state.
Results

General global gene expression observations
The SAGE method generates short sequences (i.e. 14 base-pairs transcript tags) specific to each expressed gene. The relative presentation of each tag in the overall tag population is proportional to the corresponding mRNA abundance in the original total cellular transcript population. Comparative expression profiles can be then deduced by comparing the abundance of individual tags within each sample set.
In this study, we generated SAGE libraries from p53 wt and the p53 null untreated mammary epithelial cells and from mammary epithelial cells exposed to hormonal treatment, i.e. from mammary gland transplants into mice bearing pituitary isografts for 5 weeks. In summary we generated four different mammary epithelial cell SAGE libraries analysing a total of approximately 260 000 transcript tags (over 64 000 tags/ library), which allowed us to compare the expression profile of 14 228 different transcript tags (i.e. potential genes). Of these, approximately 80% of the tags showed matches to GenBank databases either as known genes or ESTs (Expressed Sequence Tags), the remaining 20% of tags showed no matches to these databases.
Comparison of the SAGE tag libraries from p53 wt vs p53 null mammary gland under both conditions (i.e. either untreated or after hormonal exposure) demonstrated remarkable similar global gene expression profiles. Figure 1 illustrates scatter plots representing the pair-wise comparisons of the relative expression of all SAGE tags detected from p53 wt vs p53 null untreated mammary glands and the same comparison for the mammary gland samples exposed to the pituitary isografts for 5 weeks. The excellent correlation coefficients (r square=0.86 and 0.89) illustrate first, the reproducibility of SAGE using four independently generated libraries from in vivo samples and second, the close similarity of the expression profiles obtained. On the other hand and as expected, dramatic changes in expression were observed when comparing the expression profiles of mammary gland epithelial cells exposed to hormonal stimulation (i.e. pituitary isografts) vs the profile of untreated mammary epithelial cells.
Effects of exposure to pituitary hormones on mammary gland gene expression
Comparative statistical analyses of the tag libraries was performed to estimate the likelihood that a detected difference in expression would be seen by chance for each individual tag and taking into consideration the total size of the SAGE libraries being compared (Zhang et al., 1997) . As mentioned, the comparative SAGE profile of libraries from untreated mammary gland samples from wt mice with libraries from hormonally exposed animals yielded important differences. We determined that a total of 183 transcript tags changed significantly in expression (increasing or decreasing) 5threefold levels and at the P50.0005 level of significance (204 transcripts at the P50.001 level). These numbers amount to approximately 2% of the transcriptome analysed in such pair-wise comparison (*9746 transcripts total). Table 1 displays most of the transcripts identified by SAGE which increased expression at 5threefold, in the hormonally stimulated mammary gland samples (excluding tags matching ribosomal proteins, mitochondrial sequences and tags with multiple matches and non-reliable matches). Tags were arbitrarily separated in categories according to gene function. As expected the most significant changes in expression were observed on genes related to the functional differentiation of the mammary epithelium and milk production. Four tags increased above 150-fold: the tags for caseins b (891-fold), a (307-fold) and g (179-fold) and whey acidic protein (166-fold) ( Table 1) . Six tags increased between 50 -150-fold, these include tags for serum amyloid A1/A2, lactalbumin a, casein k, secreted phosphoprotein 1 (osteopontin) and one no match tag. Ten transcript tags were observed increasing between 20 -40-fold, among those we observed additional tags matching possible alternative transcripts of casein beta, adipose differentiation related protein (Adfp) (36-fold), glycosylation dependent cell adhesion molecule (Glycam1) (24-fold), ferritin heavy chain (Fth) and serum amyloid A3 (Saa3).
Several of the transcripts that showed increased expression encode for secreted proteins usually found in the extracellular compartment, and surface or cell adhesion related proteins (Table 1) . Within this group of transcripts, we include the aforementioned, secreted phosphoprotein 1 (osteopontin), and Glycam1. The tag identifying the transcript for the extracellular proteinase inhibitor (Expi or Wdnm1), a known marker of mammary gland functional differentiation, increased almost 10-fold from 33 tags in the untreated to 326 tags in hormone-stimulated mammary gland. The transcript for Mucin-4 (homolog for rat ascites sialoglycoprotein), also increased 20-fold. Interestingly, among cell surface genes increasing in expression by about 6 -7-fold we found CEA-related cell adhesion molecule 1 (Ceacam1) and CD9 antigen, a gene possibly implicated in cell motility and cell adhesion. The transcript for MMP3 (Stromelysin-1), increased by fourfold (16 -64 tags).
The high levels of circulating steroid hormones (primarily progesterone) induced by the pituitary isografts, increased the expression of a number of genes related to oxidative stress and detoxification. Among these, was cytochrome P450, 1b1, benz[a]anthracene inducible-Cyp1b1, an enzyme capable of oxidizing steroids, fatty acids and xenobiotics (10-fold increase). Other relevant enzymes include peroxiredoxin 1, glutathione peroxidases 1 and 4 and glutamatecysteine ligase, the enzyme in charge of the first and rate limiting step in de novo glutathione synthesis.
Intriguingly we also observed an increase in two tags identifying Ramp2, receptor (calcitonin) activity modifying protein 2, an enzyme that interacts with the calcitonin receptor-like receptor, modifies its ligand specificity and forms the adrenomedullin specific receptor. Calgranulin A and Calmodulin transcripts were also observed increasing in expression in the pseudo-pregnant state.
Miscellaneous other metabolism related proteins were observed increasing with the hormone treatment. Several ESTs and currently unidentified genes (no match tags) were also detected by the SAGE analysis. As can also be observed in Table 1 , changes in gene expression detected in the p53 null samples were very similar to those detected with the wt counterparts. More detailed information on these and the rest of the gene targets identified, including those downregulated by the hormonal exposure, can be found in a searchable database available at the web site http:// sciencepark.mdanderson.org/ggeg. There the complete SAGE database containing the list of the 14 228 tags identified as expressed in mouse mammary gland as well as their relative expression levels in the four conditions can be analysed via an interactive search tool. In addition all possible comparisons among samples can be performed at various fold and statistical levels of significance as well as searches on specific gene descriptors, loci or Unigene numbers. The results of each search are displayed as tag and Unigene active links to SAGEmap and the Unigene web sites; databases maintained by the National Center for Biotechnology Information (Lal et al., 1999) .
Comparative gene expression profiles of p53 wt vs p53 null mammary epithelium
The vast majority of the transcripts detected did not change significantly in expression when comparing the p53 wt with p53 null SAGE libraries (Figure 1 ). In the comparison of the untreated samples only 82 tags (0.86% of the total) were found to change in expression 5threefold at the P50.001 level of significance, and 64 tags at the P50.0005 level. The more reliable matching tags of those 64 tags are listed in Table 2a . We excluded from the table those tags matching ribosomal proteins, mitochondrial sequences, and those with non-reliable matches. A total of 12 additional tags that varied significantly between samples had no matches to current GenBank entries indicating that they likely represented novel genes (data not shown).
Interestingly, among the genes upregulated in the p53 null compared to the p53 wt untreated mammary gland were two tags identifying the extracellular proteinase inhibitor gene (Expi or Wdnm1) with the more abundant tag CTTGGCTCCT increasing from 33 to 124. Other intriguing targets that showed increased expression in the p53 null condition were the earlier described Ramp2 and a gene identified as upregulated during skeletal muscle growth 5 (Usmg5). We also observed upregulation of genes related with immune and inflammatory response. Among these, we detected a 10-fold increase in tags identifying a cluster of transcripts mapping to the Histocompatibility 2, K region locus, as well as upregulation of the Beta 2 Microglobulin gene, (B2m). These proteins are components of the Major Histocompatibility Complex (MHC) class I antigens, which are expressed in all cell types.
Similar numbers of tags were found down-regulated in the p53 null mammary epithelial cells. Again, various tags matched anonymous EST sequences. Among potentially interesting downregulated targets were the transcripts for Zinc Finger Protein 36 (Zfp36), Gprotein-coupled receptor 56 (serpentine receptor) and LIM and SH3 protein 1. Also detected was a significant downregulation of a transcript (Expressed sequence AA591047) highly homologous to Plectin1, an intermediate filament binding protein that crosslinks the cytoskeleton to the plasma membrane. We also observed a significant decrease in number for one of various tags matching likely alternative transcripts for the telomerase binding protein p23, a chaperone protein binding telomerase and the progesterone receptor. However, it was not possible to validate this observation by Northern analysis.
When comparing the pituitary isograft exposed mammary gland samples from p53 null and wt mice, the number of transcripts significantly changing in expression was even lower (Figure 1, right panel) . In this case, only 24 tags (0.25% of the total) were found to increase or decrease in expression 5threefold at the P50.001 level, and 14 at the P50.0005 level. The more reliable matches of those tags are shown in Table   2b . Thus, in either condition (untreated or hormonally exposed) more than 99% of the transcripts did not change significantly in expression when comparing p53 wt with p53 null mammary epithelial cells. Several of the tags found upregulated in the p53 null condition identified again, as in the comparison of the untreated samples, genes associated with the MHC class I antigens (Histocompatibility 2, K region locus, and B2m), genes expressed in all cell types. However, two tags identified MHC class II molecules (H2-Ab1 and Ii). The possibility exists that these transcripts could be due to infiltrating inflammatory cells. One transcript tag showing a marked increase in hormone-stimulated p53 null cells was that matching an intracisternal A particles (IAP) sequence. However, since IAP sequences are found integrated in the 3' UTR of numerous genes, it is difficult to ascertain the relevance of this observation. Very few genes were found significantly down-regulated (at the P50.0005 level) in the comparison of the hormonally exposed samples. Among them was the phospholipase c neighboring gene (homologue to protein phosphatase I, regulatory subunit 14B) (Table 2b) .
Validation of specific SAGE findings
The effects of a p53 null genotype on the expression in mammary epithelium of specific genes were confirmed by Northern analysis. To this end total RNA was isolated and Northern analyses performed on parallel samples to those analysed by means of SAGE. As can be observed in Figure 2 , the Northern analysis for Expi/Wdnm1, confirmed the SAGE observations. As expected a dramatic increase in Expi expression was observed in hormone treated cells but more importantly a very significant increase in expression in the untreated p53 null sample when comparing with the p53 wt counterpart. Analysis of the B2m transcript demonstrated an identical trend, also confirming the SAGE determinations (Figure 2) .
Expression of the Ramp2 gene was validated using duplex RT -PCR (data not shown) since no detection was possible by Northern blot using total RNA. We observed a correlation in expression with that detected by SAGE although with differences of lower magnitude (*3 -4-fold RAMP2 upregulation in p53 null vs p53 wt (untreated samples). The transcripts shown in Tables 1 and 2 represent only those differences found at a very high level of significance, i.e. with practically no statistical chance for false positives. Nevertheless, although with a higher level of uncertainty, analysing data from less significant differences still may identify gene targets of interest as predicted by SAGE. One example of this is shown in Figure 3 in which we investigated the expression of the gene Gelsolin (Gsn) which SAGE identified as with lower expression in the hormonally exposed p53 null sample at seven tags vs 20 tags in the wt (P=0.006). As can be observed the SAGE finding was also confirmed by Northern analysis as well.
In order to extend these observations and explore whether some of the genes identified could serve as markers of preneoplastic progression, we analysed the expression levels of the mentioned genes in two transplantable preneoplastic mammary epithelial cell outgrowth lines. These two mammary epithelial outgrowths were derived from p53 null cells and differ dramatically in their tumorigenic potential, as described in the Materials and methods section (Medina et al., 2002) . The pattern of expression found in the preneoplastic outgrowth lines, using the three genes mentioned above, Expi, B2m and Gelsolin, matched the profile inferred from analysing the untreated and hormonally stimulated original samples. The most aggressive mammary epithelial line PNIa showed a much higher expression of Expi, a similar trend for B2m, while no detectable expression of Gelsolin was observed (Figure 4) .
Analysis of other p53 regulated genes
As mentioned above many other differentially expressed genes of interest are not displayed in Table  2 simply because the difference in tag representation did not reach the stringent statistical significance cutoff level used. In Table 3 we report the SAGE expression status of some transcripts known to be p53 target genes, some recently reported p53 regulated genes in other models and other genes of interest (Cui and Donehower, 2000; Zhao et al., 2000) .
Among the classical known p53 targets, two reliable tags were found matching the p21 (Cdkn 1a) gene. One of these tags was found differentially expressed in the untreated samples (10 tags in the p53 wt to five tags in the p53 null ) and the second tag which identifies a transcript with a shorter 3' end, was differentially expressed in the treated samples 11 to 3 respectively (a Figure 2 Validation analysis of specific transcripts with dysregulated expression in p53 null mammary epithelium. Northern blot analyses of total RNA obtained from p53 null and p53 wt mammary epithelial samples, untreated and hormonally stimulated (i.e. pituitary isografts bearing hosts) as indicated. Expression of both transcripts Expi (Wdnm1) and B2m validated the SAGE determinations. Higher expression was observed in the hormonally stimulated samples but more importantly upregulation of both transcripts was observed in the untreated p53 null epithelium when compared with the p53 wt counterpart. Lower panel shows the 18SrRNA bond from the ethidium bromide stained Northern blot membrane to demonstrate loading levels of the samples 3.7-fold lower expression in the p53 null sample, P=0.02) (Table 3 ). Among other cell cycle related known p53 target genes, there was not a significant differential expression of the tag identifying Gadd45 a; however there was a 2.8-fold lower level expression of Gadd45 b in p53 null untreated samples (11 tags to 4) and a 2.4-fold lower level in p53 null hormonally stimulated mammary gland compared with p53 wt (12 tags to five). The tag identifying 14-3-3 sigma (Mkrn3, makorin ring finger protein 3) was detected as marginally differentially expressed in the hormonally stimulated samples, 40 tags in the p53 wt vs 23 tags in the p53 null (P=0.01). No significant tag representation was detected for the known p53 targets Mdm2, Bax and other apoptosis related genes.
It has been previously reported the p53 upregulation of differentiation and cytoskeletal related genes such as various keratins in cell culture models and in tumors (Cui and Donehower, 2000; Zhao et al., 2000) . In agreement with those observations, we detected significant lower expression in p53 null mammary gland of Keratin 18 (2.6-fold lower in untreated samples and almost twofold lower in hormonally exposed samples). Keratin 14 was also expressed at a 2.1-fold lower level in hormone-stimulated p53 null mammary gland samples (P=0.001). (Medina et al., 2002) . PNIa displays a highly tumorigenic phenotype while PNIb is characterized by a milder low tumorigenic phenotype (see Materials and methods section). Transcripts with abnormal expression in p53 null mammary epithelium were detected as differentially expressed in the mammary outgrowth lines. PNIa, the most aggressive line showed higher expression of Expi, a similar trend for B2m and no detectable expression of Gelsolin Using oligonucleotide hybridization technology and in vitro models, Zhao et al. (2000) reported the p53 regulation of various other genes. Our SAGE results show a general agreement on the effects of p53 over the expression of several of those genes, as shown in Table  3 . Igfbp3, a gene known to be activated by p53, was detected at very low level of expression; nevertheless, the wt untreated mammary gland showed five tags vs none in the p53 null sample. Igbp5 was detected at higher levels but with the same tendency, showing 7.5-fold higher level in the p53 wt untreated sample (P=0.002) and almost twofold higher in the hormonally treated p53 wt mammary cells (P=0.02). One of the genes reportedly repressed by p53 is superoxide dismutase 3 (Zhao et al., 2000) . We did not detect tags matching Sod3, but interestingly we detected differential expression for superoxide dismutase 2 (Sod2), with a higher number of tags in the p53 null untreated mammary gland (10 tags) compared to the wt (two tags, P=0.01). Sod1 followed the same trend, but did not reach statistical significance (one tag vs 5). Other reported p53 repressed genes that showed significant differential expression include CCAAT/ enhancer binding protein (C/EBP), delta; Hmgn2 (mouse homolog of human HMG17) and protothymosin alpha (Ptma) all at higher levels in p53 null cells (Table 3) .
Discussion
In this study we used SAGE, a powerful and comprehensive methodology, to profile the transcriptome of mammary epithelial cells in which the p53 gene had been knocked out. This study is unique as it focused on an in vivo model of preneoplastic phenotype and examined the transcriptome of morphologically 'normal' cells prior to any histopathological changes. In this model, the mammary epithelial transplants derived from both genotypes (p53 null and p53 wt ) develop identical gland structures with no detectable differences at the gross morphological or histological level (Goepfert et al., 2000; Jerry et al., 2000) . By 7 weeks after transplantation, the mammary epithelial cells completely fill the mammary fat pad of the virgin hosts with normal duct. In the presence of hormone stimulation, both genotypes exhibit complete lobuloalveolar differentiation equivalent to late pregnancy (Goepfert et al., 2000) . It was observed in this system that by 5 months posttransplantation the hormonally stimulated p53 null transplants start developing mammary adenocarcinomas rapidly reaching a 100% incidence in a few months; in contrast, no tumors are observed in the p53 wt counterparts (Jerry et al., 2000) . In their progression towards malignancy it is common to observe premalignant lesions such as atypical ductal hyperplasias and carcinoma in situ lesions. Interestingly these lesions express estrogen and progesterone receptors and become aneuploid, thus mimicking closely the human breast carcinogenesis process (Medina et al., 2002) .
We determined that the global gene expression profile of mammary epithelial cells from wt and p53 null animals were extremely similar, in particular, in the proliferating condition in which a very limited number of genes was detected as differentially expressed. Among these were a set of genes that might be potentially premalignant markers. These include Expi/ Wdnm1, Ramp2 and Usmg5. It is important to stress that in order to avoid false positives and to identify truly differentially expressed genes between the p53 null and wt samples, we used a very stringent statistical cutoff criteria, focusing only on tags differentially represented at a P50.0005 by Monte Carlo analysis (Zhang et al., 1997) .
The putative extracellular proteinase inhibitor Expi or Wdnm1 was already known to increase expression early in pregnancy and during alveolar proliferation (Robinson et al., 1995) and SAGE detected such increase in expression accurately when comparing the untreated mammary samples vs the hormonally stimulated epithelium. This protein is a member of the four-disulfide core family of proteins like Whey Acidic Protein, a protein that also increases dramatically its expression during functional differentiation. But more importantly than the observed increase of Expi in the hormonally stimulated mammary gland, we detected this gene as differentially expressed in the resting (untreated) mammary gland samples showing much higher expression in the p53 null samples when compared with the wt. The SAGE results were confirmed by Northern analyses. The behavior in expression of this marker of mammary epithelial functional differentiation appears intriguing and specific since we did not observe differential expression of other functional differentiation markers such as the casein genes in the resting mammary epithelial samples. The rat homolog of this gene (WDNM1) was originally identified as a transcript with decreased expression in metastatic rat mammary adenocarcinomas (Dear et al., 1988) . Interestingly, it was postulated that Expi/ Wdnm1 could be a marker of Neu and Ras initiated mouse mammary adenocarcinomas since it was observed as highly expressed in such tumors but absent in Myc and Int-2 induced counterparts (Morrison and Leder, 1994 ). Here we demonstrated that Expi/Wdnm1 behaves as a potential premalignant marker since it was not only found highly expressed in the resting p53 null mammary gland but also showed the highest expression in the more aggressive premalignant mammary outgrowth line PNIa. Although the true function of Expi is unclear, the expression of this secreted putative extracellular proteinase inhibitor may be of importance in extracellular matrix remodeling and perhaps early stages of tumor invasion.
SAGE also detected the transcript for Ramp2 as upregulated in p53 null cells and this observation was confirmed by RT -PCR analysis. Ramp2 is a member of a family of single-transmembrane-domain proteins called receptor (calcitonin) activity modifying proteins (RAMPs). These proteins are required to transport the calcitonin-receptor-like receptor (Crlr) to the plasma membrane. It is postulated that the specific Ramp member -Crlr combination defines the ligand affinity of the receptor for either Calcitonin or Adrenomedullin (Adm) (McLatchie et al., 1998) . Ramp2 is postulated to confer Adm specificity for the Crlr. Adm has been shown to play multiple functions and was originally discovered as a potent vasorelaxing and natriuretic peptide. Adm is normally expressed by several cell types, but interestingly, it was observed as expressed by various tumor cells as well (Oehler et al., 2001) . Further association of Adm with carcinogenesis has been reported, as this peptide has angiogenic properties and is upregulated under hypoxic conditions (Oehler et al., 2001; Zhao et al., 1998) . Recently, it was also reported that Adm may inhibit hypoxic cell death via upregulation of Bcl2 (Oehler et al., 2001) . The significance of Ramp2 upregulation in p53 null samples is intriguing because it may establish Adm, a gene with putative angiogenic and anti-apoptotic properties, as a potent tumor promoter in this system.
We also observed in p53 null samples the upregulation of various transcripts associated with the MHC (HLA in humans) class I antigens; among these, we validated the increase in expression of B2m. These proteins play an important role in cellular immunology by presenting antigens to T cells. When the MHC complex is metabolized, the B2m protein is shed into the serum and milk. Interestingly, the presence of elevated mean B2m serum levels in breast cancer patients as compared to controls have been previously reported (Klein et al., 1991) . The relevance of our finding on dysregulated expression of MHC class I antigens in p53 null cells is unclear at this point. Interestingly however it has also been reported that the human HLA-B core promoter is repressed by wild type p53 and this would be in agreement with our observations (Griffioen et al., 1998) .
Using lower but still very stringent statistical cutoff criteria we identified differential expression of numerous other interesting genes including, Gelsolin, Cyp1b1 and known p53 regulated genes. SAGE detected lower abundance numbers for the tag identifying Gelsolin in the p53 null samples, both for the untreated and hormonally stimulated mammary epithelial cells, when compared with the wt counterparts. We confirmed these observations by Northern analysis. When we extended this analysis to the mammary outgrowth lines strikingly we observed that Gelsolin expression was not detected in the more aggressive line compared to the line with milder phenotype. Gelsolin is a calciumdependent protein that regulates actin filament length. It severs assembled actin filaments in two and caps the ends of free and growing actin filaments (reviewed by Kwiatkowski, 1999 ). It appears to play a critical role in cell motility and it may participate in lipid signaling pathways as well. It has been shown that Gelsolin may play a role in mediating apoptosis progression consequential to being a major substrate of Caspase3 proteolysis. Interestingly, and in agreement with our findings, Gelsolin was found downregulated in several tumor types including breast cancer (Asch et al., 1996) . Furthermore, it was observed downregulated at preinvasive stages of human breast carcinogenesis (Winston et al., 2001) .
The observed downregulation for Gelsolin, for various keratin genes, and for a sequence highly homologous to Plectin1, indicates that remodeling of the mammary epithelial cell cytoskeleton appears to be affected very early in the p53 null condition and probably such changes may have important repercussion for cell motility, morphology and likely, viability.
The gene Cyp1b1 was also detected as differentially expressed. This cytochrome p450 enzyme appears to fundamentally contribute to estradiol metabolism in mammary epithelium and it is found expressed in most breast cancers (reviewed by Williams and Phillips, 2000) . Cyp1b1 is a specific estradiol 4-hydroxylase generating 4-hydroxyestrone and it has been postulated that the further activation of this cathecol to reactive intermediates can contribute to mammary carcinogenesis (Williams and Phillips, 2000) . In addition, Cyp1b1 can participate in the metabolic activation of various carcinogens such as polycyclic aromatic hydrocarbons, heterocyclic amines and aromatic amines. We detected a 4.8-fold significant difference in expression for Cyp1b1 when comparing the resting (untreated) mammary gland epithelial samples from p53 wt vs p53 null mice (four tags to 19 respectively, P=0.0006) (Tables 1 and 3 ). This permits us to speculate that perhaps the p53 null mammary epithelium is at higher risk of being exposed to potentially carcinogenic estrogen metabolites and other carcinogenic xenobiotics. In accordance with this speculation, continuous exposure of the p53 null mammary epithelium to low doses of estrogen (20 mg pellet for 6 weeks) results in enhanced tumorigenicity (75% tumor incidence) by 45 weeks post-transplantation. This same dose and exposure does not convey any tumorigenic potential to p53 wt mammary epithelium (D Medina, unpublished observations).
We also analysed the expression of various previously known p53 regulated genes and compared their expression as detected by SAGE. In summary and as a general validation to the approach followed, it was encouraging to find that most genes known to be activated by p53 showed lower numbers of tags in the p53 null samples than in the wt counterparts, and vice versa, genes reported to be repressed by p53 showed a tendency to higher numbers of tags in the p53 null samples (Table 3) . Interestingly, p53-regulated genes involved in the apoptotic pathway were not found differentially expressed. This is in accordance with our observations that there is no significant difference in apoptotic activity in either normal or premalignant p53 null mammary epithelium compared to p53 wt mammary epithelium (Medina et al, 2002) . This study also allowed us to appreciate the dramatic gene expression effects generated in the mammary epithelial cells by the induction of a pseudo-pregnant state. In the samples, both from wt and p53 null cells, at the top of the most abundantly expressed genes, as expected, were all the milk-related proteins. We also observed a significant increase in expression of several secreted proteins that likely play important roles in extracellular matrix remodeling. Increasing in expression were also transcripts for iron transporting proteins such as the ferritin chains and lactotransferrin. We detected upregulation of numerous transcripts associated with oxidative stress and detoxification of xenobiotics and steroid metabolites. This was probably consequential to the high levels of steroid hormonal exposure. The SAGE analysis of the untreated vs the hormonally stimulated mammary epithelium, provided an excellent verification of the power of the technique employed to assess gene expression changes, as it identified most genes that are known to be upregulated in the alveolar differentiation process as well as potentially some novel genes.
In summary, this study is the first to examine the transcriptome of very early stages of preneoplastic progression in an in vivo model that is also relevant for human breast cancer. The study determined that less than 1% of the transcriptome is dysregulated as a consequence of loss of p53 function but that among the genes dysregulated there were several that might serve as potential markers for premalignant progression. Future studies will focus on the functional characterization and mechanistic aspects of the most promising genes from the list of such potential preneoplastic biomarkers.
Materials and methods
Mammary gland epithelial samples
Donor mammary ducts were dissected from the glands of 8-week-old p53 null and p53 wt Balb/c female mice and transplanted into the cleared mammary fat pads of 3-weekold syngeneic female mice as previously described (Medina, 1996) . In order to induce mammary gland lobuloalveolar development, at 5 weeks of age, some of the recipient mice (n=5) received a pituitary isograft under the kidney capsule (i.e. hormonally stimulated mammary gland samples), while other mice (n=10) were left untreated. At 7 weeks post transplantation (i.e. 5 weeks of hormonal stimulation), the mammary glands containing the transplants representative of both conditions (p53 null and p53 wt ) from hormonally treated and untreated mice were dissected and epithelial enriched cell pellets (490% pure epithelial cells) were prepared by short term collagenase digestion as previously described . Samples were snapped frozen for subsequent RNA isolation for SAGE and Northern analyses.
Northern analyses were also performed on RNA obtained from two transplantable p53 null mammary ductal outgrowth lines, generated independently. These two transplantable outgrowth lines, PNIa and PNIb, are characterized by their markedly dissimilar tumorigenic potential as described elsewhere (Medina et al., 2002) . Briefly, PNIa is a very aggressive outgrowth line which produces 78% mammary adenocarcinomas in a very short time (6 months after transplantation) in the host mice while PNIb displays a much milder phenotype and produces only 15% of tumors at 12 months after transplantation (Medina et al., 2002) .
SAGE and validation assays
Total RNA was isolated using the Qiagen total RNA Maxi kit (Qiagen) and mRNA was purified using the Oligotex mRNA kit (Qiagen) following the manufacturer's protocol. cDNA was synthesized and global gene expression profiles were obtained and analysed using the SAGE methodology as previously described (Charpentier et al., 2000; Velculescu et al., 1995) . Statistical analysis and comparison between the different SAGE libraries was performed as described previously and by using statistical functions available in the SAGE 3.0 software (kindly provided by Dr K Kinzler, John Hopkins University) for P value calculations and Monte Carlo simulations (Zhang et al., 1997) .
For Northern blot analysis, total RNA was isolated and hybridizations performed following standard procedures. Probes for hybridization were synthesized by RT -PCR from a pool of mouse cDNAs, the specific amplified products were cloned and their sequence confirmed by standard automatic DNA sequencing before use.
Duplex RT -PCR was performed using primers for detection and quantifying Ramp2 expression (forward primer 5'-GGGAAGATGGAAGACTACGA-3' and reverse primer 5'-GGCTGCTGAGAAATGGAC-3') and as an internal reference control Gapdh (forward primer 5'-GGTGCTGAG-TATGTCGTGGA-3' and reverse primer 5'-GCCATGCCA-GTGAGCTTCCC-3'). PCR products were resolved by electrophoresis on a 3% agarose gel. After staining with Vista Green (Amersham Biosciences) analysis on the relative intensity of each amplified product was performed using a FluorImager SI (Amersham Biosciences).
